Nutrients
GLP-1-Based Pharmacotherapies and Skeletal Muscle Health in Obesity: A Narrative Review of Body Composition, Muscle Function, and Sarcopenia-Related Outcomes
By Justyna Knapik, Weronika Fic and Ewelina Polak-Szczybyło.
Abstract
Background
Obesity is associated with impaired skeletal muscle health and sarcopenic obesity. GLP-1-based pharmacotherapies induce weight loss, but accompanying reductions in fat-free or lean mass raise concerns about skeletal muscle loss. Conversely, reductions in adiposity, inflammation, insulin resistance, and intramuscular fat may be beneficial.
Objective
This narrative review evaluated the effects of GLP-1-based pharmacotherapies on body composition, muscle quantity, composition and function, and their potential role in sarcopenia.
